Acadian Asset Management LLC Makes New $813,000 Investment in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)

Acadian Asset Management LLC purchased a new stake in shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) in the 2nd quarter, Holdings Channel reports. The fund purchased 695,972 shares of the biopharmaceutical company’s stock, valued at approximately $813,000.

Other large investors have also recently modified their holdings of the company. SG Americas Securities LLC bought a new stake in Marinus Pharmaceuticals during the 2nd quarter valued at $34,000. Values First Advisors Inc. raised its holdings in shares of Marinus Pharmaceuticals by 501.8% in the second quarter. Values First Advisors Inc. now owns 62,671 shares of the biopharmaceutical company’s stock valued at $73,000 after acquiring an additional 52,257 shares in the last quarter. Hussman Strategic Advisors Inc. lifted its stake in Marinus Pharmaceuticals by 14.3% in the second quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the biopharmaceutical company’s stock worth $98,000 after acquiring an additional 10,500 shares during the period. Jacobs Levy Equity Management Inc. bought a new position in Marinus Pharmaceuticals during the 1st quarter worth about $384,000. Finally, Trexquant Investment LP purchased a new position in Marinus Pharmaceuticals during the 4th quarter valued at about $553,000. Hedge funds and other institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Stock Up 3.3 %

Shares of MRNS stock opened at $1.55 on Tuesday. The company has a market cap of $85.15 million, a price-to-earnings ratio of -0.59 and a beta of 1.13. Marinus Pharmaceuticals, Inc. has a 1-year low of $1.05 and a 1-year high of $11.26. The company has a debt-to-equity ratio of 5.68, a current ratio of 2.28 and a quick ratio of 2.15. The stock’s fifty day moving average price is $1.35 and its 200 day moving average price is $3.00.

Marinus Pharmaceuticals (NASDAQ:MRNS) last issued its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.01). The firm had revenue of $8.06 million for the quarter, compared to analyst estimates of $9.05 million. Marinus Pharmaceuticals had a negative return on equity of 7,831.35% and a negative net margin of 493.14%. During the same period in the prior year, the firm posted ($0.61) EPS. On average, research analysts expect that Marinus Pharmaceuticals, Inc. will post -1.88 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently issued reports on MRNS. Cantor Fitzgerald reiterated an “overweight” rating and set a $13.00 price objective on shares of Marinus Pharmaceuticals in a research note on Monday. StockNews.com raised Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, September 9th. LADENBURG THALM/SH SH downgraded Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Wednesday, August 14th. Truist Financial restated a “buy” rating and set a $10.00 price objective on shares of Marinus Pharmaceuticals in a research note on Tuesday, June 18th. Finally, HC Wainwright reiterated a “buy” rating and issued a $11.00 target price on shares of Marinus Pharmaceuticals in a research note on Wednesday, August 14th. Five analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $10.25.

Marinus Pharmaceuticals Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.